Abbott Laboratories acquired a 9.6% stake in NeoGenomics, a cancer genetics laboratory for US$4.8 M. The agreement also provides for Abbott to supply materials to NeoGenomics to develop its own FISH (fluorescence in-situ hybridization)-based test to diagnose melanoma.